Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H2 2016

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H2 2016', provides in depth analysis on Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Overview 8

Therapeutics Development 9

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Products under Development by Stage of Development 9

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Products under Development by Therapy Area 10

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Products under Development by Indication 11

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Products under Development by Companies 14

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Products under Development by Universities/Institutes 16

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Companies Involved in Therapeutics Development 24

AMO Pharma Limited 24

Angelini Group 25

Celon Pharma Sp. z o.o. 26

DiaMedica Inc. 27

HitGen LTD 28

Jeil Pharmaceutical Co., Ltd. 29

Mitsubishi Tanabe Pharma Corporation 30

Neurim Pharmaceuticals Ltd 31

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Drug Profiles 32

AP-001-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CPL-202100-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

DM-199-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

DM-204-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Drug to Inhibit GSK3-Beta for Alzheimer's Disease-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

IB-AD-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

JGK-263-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

manzamine A-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Neu-120-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecule to Inhibit GSK3b for Type 2 Diabetes-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer's Disease-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

tideglusib-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Dormant Projects 52

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Discontinued Products 54

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Featured News & Press Releases 55

Oct 05, 2016: DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199 55

Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 55

Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy 55

Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 56

Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 56

Nov 04, 2015: DiaMedica Provides Corporate Update 57

Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 58

Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases 58

Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes 59

Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes 59

Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference 59

Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199 60

Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients 60

Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients 60

Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by AMO Pharma Limited, H2 2016 24

Pipeline by Angelini Group, H2 2016 25

Pipeline by Celon Pharma Sp. z o.o., H2 2016 26

Pipeline by DiaMedica Inc., H2 2016 27

Pipeline by HitGen LTD, H2 2016 28

Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 29

Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 30

Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 31

Dormant Projects, H2 2016 52

Dormant Projects (Contd..1), H2 2016 53

Discontinued Products, H2 2016 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AMO Pharma Limited, Angelini Group, Celon Pharma Sp. z o.o., DiaMedica Inc., HitGen LTD, Jeil Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Neurim Pharmaceuticals Ltd

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Therapeutic Products under Development, Key Players in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Therapeutics, Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Pipeline Overview, Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Pipeline, Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com